New Brunswick Scientific Co., Inc. (NBSC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : New Brunswick Scientific Co., Inc. (NBSC)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote ()	2/21/2000 2:51:00 PM
From: scaram(o)uche	of 724

Here's a dated (5/11/98) description of the Diogenesis™ Process..... dgibt.com and from the corporate overview..... DGI BioTechnologies L.L.C. is using its proprietary "Diogenesis™" process to accelerate drug discovery by providing an universal in vitro assay system for rapid identification of orally-active small organic compounds. DGI's Diogenesis™ constitutes the first in vitro site-directed discovery platform that is geared to find small molecule regulators of protein:protein interactions. It restricts the compound selection process to leads known to possess all of the attributes of an active pharmaceutical compound: affinity, selectivity, and biological activity toward desired targets. Recognition of small molecules exhibiting these key characteristics offers the industry a new route to orally active replacements for large protein hormones and other active factors as well as significantly reduced time, effort, and costly repetitive assays to recognize true leads among hundreds of thousands of candidate compounds. Sounds like it would be a good fit with certain efforts at Ligand. Moreover, sounds like a set of tools that would integrate smoothly with a proteomics effort.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next